Clinuvel Pharmaceuticals Ltd
SWB:UR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Clinuvel Pharmaceuticals Ltd
SWB:UR9
|
AU |
|
Global Investments Ltd
SGX:B73
|
SG |
|
Parkmead Group PLC
LSE:PMG
|
UK |
|
China Resources Land Ltd
OTC:CRBJF
|
HK |
|
M
|
MTR Corp Ltd
XMUN:MRI
|
HK |
|
Fideicomiso Irrevocable No F/1401
OTC:FBASF
|
MX |
|
Cettire Ltd
ASX:CTT
|
AU |
Wall St Price Targets
UR9 Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for UR9 is 9.04 EUR with a low forecast of 5.91 EUR and a high forecast of 25.35 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is UR9's stock price target?
Price Target
9.04
EUR
According to Wall Street analysts, the average 1-year price target for UR9 is 9.04 EUR with a low forecast of 5.91 EUR and a high forecast of 25.35 EUR.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 39%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
The compound annual growth rate for Gross Profit over the next 8 years is 8%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Pre-Tax Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
12%
The compound annual growth rate for Pre-Tax Income over the next 4 years is 12%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
11%
The compound annual growth rate for Net Income over the next 8 years is 11%.